Loading...
Please wait, while we are loading the content...
Similar Documents
Helicase primase: targeting the Achilles heel of herpes simplex viruses
| Content Provider | CiteSeerX |
|---|---|
| Author | Kleymann, Gerald |
| Abstract | The majority of the population is infected by sev-eral herpesviruses. Once these infections are established the viruses persist for life. Therefore, current therapy may at best reduce symptoms but does not cure the infection. Moreover, the only classes of compounds licensed for systemic treat-ment of disease are nucleoside, nucleotide and pyrophosphate analogues; all of these ultimately target the herpesvirus DNA polymerase. A vaccine against varicella zoster virus (VZV) is available, but so far no effective vaccines against other human herpesviruses have been launched. At the same time, rising resistance to current medication, espe-cially in the immunocompromised patient popula-tion, is a concern. For these reasons, there is an urgent need for new treatment options. Recently, some promising new drugs have been discovered; one of these compounds, developed at Bayer HealthCare under the name BAY 57-1293, is a potent HSV helicase primase inhibitor. |
| File Format | |
| Access Restriction | Open |
| Content Type | Text |
